In the claims:

1. (Original) A method of identifying a hair growth modulator comprising:

identifying a P-cadherin modulator; and

testing whether said P-cadherin modulator is functional as a hair growth modulator.

2. (Withdrawn) The method of claim 1, wherein said P-cadherin modulator is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

3. (Withdrawn) The method of claim 1, wherein said P-cadherin modulator is an antisense construct encoding an antisense transcript capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

4. (Withdrawn) The method of claim 1, wherein said P-cadherin modulator is a polynucleotide capable of directing P-cadherin expression in hair follicle cells.

5. (Withdrawn) The method of claim 1, wherein said P-cadherin modulator is an anti-P-cadherin antibody.

6. (Withdrawn) The method of claim 1, wherein said P-cadherin modulator is an a small molecular weight organic compound.

7. (Original) The method of claim 1, wherein said P-cadherin modulator is a peptide.

8. (Withdrawn) A hair growth modulator identified by the method of claim 1.

9. (Withdrawn) A method of modulating hair growth comprising administering to a subject in need a therapeutically effective amount of the hair growth modulator of claim 8.

10. (Withdrawn) A method of identifying a hair growth modulator comprising:

identifying a molecule being capable of specifically binding to P-cadherin; and

testing whether said molecule is functional as a hair growth modulator.

11. (Withdrawn) The method of claim 10, wherein said molecule is an anti-P-cadherin antibody.

12. (Withdrawn) The method of claim 10, wherein said molecule is an a small molecular weight organic compound.

13. (Withdrawn) The method of claim 10, wherein said molecule is a peptide.

14. (Withdrawn) A hair growth modulator identified by the method of claim 10.

15. (Withdrawn) A method of modulating hair growth comprising administering to a subject in need a therapeutically effective amount of the hair growth modulator of claim 14.

16. (Withdrawn) The method of claim 10, wherein identifying said molecule being capable of specifically binding to P-cadherin is by a two hybrid system.

17. (Original) A method of identifying a hair growth inhibitor comprising:

identifying a P-cadherin inhibitor; and

testing whether said P-cadherin inhibitor is functional as a hair growth inhibitor.

18. (Withdrawn) The method of claim 17, wherein said P-cadherin inhibitor is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

19. (Withdrawn) The method of claim 17, wherein said P-cadherin inhibitor is an antisense construct encoding an antisense transcript capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

20. (Withdrawn) The method of claim 17, wherein said P-cadherin inhibitor is an anti-P-cadherin antibody.

21. (Withdrawn) The method of claim 17, wherein said P-cadherin inhibitor is an a small molecular weight organic compound.

22. (Original) The method of claim 17, wherein said P-cadherin inhibitor is a peptide.

23. (Withdrawn) A hair growth inhibitor identified by the method of claim 17.

24. (Withdrawn) A method of inhibiting hair growth comprising administering to a subject in need a therapeutically effective amount of the hair growth inhibitor of claim 23.

25. (Withdrawn) A method of identifying a hair growth inhibitor comprising:

identifying a molecule being capable of specifically binding to P-cadherin; and
testing whether said molecule is functional as a hair growth inhibitor.

26. (Withdrawn) The method of claim 25, wherein said molecule is an anti-P-cadherin antibody.

27. (Withdrawn) The method of claim 25, wherein said molecule is an a small molecular weight organic compound.

28. (Withdrawn) The method of claim 25, wherein said molecule is a peptide.

29. (Withdrawn) A hair growth inhibitor identified by the method of claim 25.

30. (Withdrawn) A method of inhibiting hair growth comprising administering to a subject in need a therapeutically effective amount of the hair growth inhibitor of claim 29.

31. (Withdrawn) The method of claim 26, wherein identifying said molecule being capable of specifically binding to P-cadherin is by a two hybrid system.

32. (Withdrawn) A method of identifying a hair growth inducer comprising:

identifying a P-cadherin inducer; and
testing whether said P-cadherin inducer is functional as a hair growth inducer.

33. (Withdrawn) The method of claim 32, wherein said P-cadherin inducer is a polynucleotide capable of directing P-cadherin expression in hair follicle cells.

34. (Withdrawn) The method of claim 32, wherein said P-cadherin inducer is an a small molecular weight organic compound.

35. (Withdrawn) The method of claim 32, wherein said P-cadherin inducer is a peptide.

36. (Withdrawn) A hair growth inducer identified by the method of claim 32.

37. (Withdrawn) A method of inducing hair growth comprising administering to a subject in need a therapeutically effective amount of the hair growth inducer of claim 36.

38. (Withdrawn) A method of identifying a hair growth inducer comprising:

identifying a molecule being capable of specifically binding to P-cadherin; and

testing whether said molecule is functional as a hair growth inducer.

39. (Withdrawn) The method of claim 38, wherein said molecule is an anti-P-cadherin antibody.

40. (Withdrawn) The method of claim 38, wherein said molecule is an a small molecular weight organic compound.

41. (Withdrawn) The method of claim 38, wherein said molecule is a peptide.

42. (Withdrawn) A hair growth inducer identified by the method of claim 38.

43. (Withdrawn) A method of inducing hair growth comprising administering to a subject in need a therapeutically effective amount of the hair growth inducer of claim 42.

44. (Withdrawn) The method of claim 39, wherein identifying said molecule being capable of specifically binding to P-cadherin is by a two hybrid system.

45. (Withdrawn) A method of modulating hair growth, the method comprising administering to a subject in need a therapeutically effective amount of a P-cadherin modulator functional as a hair growth modulator.

46. (Withdrawn) The method of claim 45, wherein said P-cadherin modulator is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

47. (Withdrawn) The method of claim 45, wherein said P-cadherin modulator is an antisense construct encoding an antisense transcript capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

48. (Withdrawn) The method of claim 45, wherein said P-cadherin modulator is a polynucleotide capable of directing P-cadherin expression in hair follicle cells.

49. (Withdrawn) The method of claim 45, wherein said P-cadherin modulator is an anti-P-cadherin antibody.

50. (Withdrawn) The method of claim 45, wherein said P-cadherin modulator is an a small molecular weight organic compound.

51. (Withdrawn) The method of claim 45, wherein said P-cadherin modulator is a peptide.

52. (Withdrawn) The method of claim 45, further comprising co-administering to the subject a therapeutically effective amount of an additional hair growth modulator.

53. (Withdrawn) A method of inhibiting hair growth, the method comprising administering to a subject in need a therapeutically effective amount of a P-cadherin inhibitor functional as a hair growth inhibitor.

54. (Withdrawn) The method of claim 53, wherein said P-cadherin inhibitor is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

55. (Withdrawn) The method of claim 53, wherein said P-cadherin inhibitor is an antisense construct encoding an antisense transcript capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

56. (Withdrawn) The method of claim 53, wherein said P-cadherin inhibitor is an anti-P-cadherin antibody.

57. (Withdrawn) The method of claim 53, wherein said P-cadherin inhibitor is an a small molecular weight organic compound.

58. (Withdrawn) The method of claim 53, wherein said P-cadherin inhibitor is a peptide.

59. (Withdrawn) The method of claim 53, further comprising co-administering to the subject a therapeutically effective amount of an additional hair growth inhibitor.

60. (Withdrawn) A method of inducing hair growth, the method comprising administering to a subject in need a therapeutically effective amount of a P-cadherin inducer functional as a hair growth inducer.

61. (Withdrawn) The method of claim 60, wherein said P-cadherin inducer is a polynucleotide capable of directing P-cadherin expression in hair follicle cells.

62. (Withdrawn) The method of claim 60, wherein said P-cadherin inducer is an a small molecular weight organic compound.

63. (Withdrawn) The method of claim 60, wherein said P-cadherin inducer is a peptide.

64. (Withdrawn) The method of claim 60, further comprising co-administering to the subject a therapeutically effective amount of an additional hair growth inducer.

65. (Withdrawn) A pharmaceutical composition for modulating hair growth, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of a P-cadherin modulator functional as a hair growth modulator.

66. (Withdrawn) The pharmaceutical composition for claim 65, wherein said P-cadherin modulator is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

67. (Withdrawn) The pharmaceutical composition for claim 65, wherein said P-cadherin modulator is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

68. (Withdrawn) The pharmaceutical composition for claim 65, wherein said P-cadherin modulator is a polynucleotide capable of directing P-cadherin expression in hair follicle cells.

69. (Withdrawn) The pharmaceutical composition for claim 65, wherein said P-cadherin modulator is an anti-P-cadherin antibody.

70. (Withdrawn) The pharmaceutical composition for claim 65, wherein said P-cadherin modulator is an a small molecular weight organic compound.

71. (Withdrawn) The pharmaceutical composition for claim 65, wherein said P-cadherin modulator is a peptide.

72. (Withdrawn) The pharmaceutical composition for claim 65, further comprising, as an additional active ingredient, a therapeutically effective amount of an additional hair growth modulator.

73. (Withdrawn) A pharmaceutical composition for inhibiting hair growth, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of a P-cadherin inhibitor functional as a hair growth inhibitor.

74. (Withdrawn) The pharmaceutical composition for claim 73, wherein said P-cadherin inhibitor is an antisense oligonucleotide capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

75. (Withdrawn) The pharmaceutical composition for claim 73, wherein said P-cadherin inhibitor is an antisense construct encoding an antisense transcript capable of specifically binding to P-cadherin gene, pre-messenger RNA or messenger RNA under physiological conditions.

76. (Withdrawn) The pharmaceutical composition for claim 73, wherein said P-cadherin inhibitor is an anti-P-cadherin antibody.

77. (Withdrawn) The pharmaceutical composition for claim 73, wherein said P-cadherin inhibitor is an a small molecular weight organic compound.

78. (Withdrawn) The pharmaceutical composition for claim 73, wherein said P-cadherin inhibitor is a peptide.

79. (Withdrawn) The pharmaceutical composition for claim 73, further comprising, as an additional active ingredient, a therapeutically effective amount of an additional hair growth inhibitor.

80. (Withdrawn) A pharmaceutical composition for inducing hair growth, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of a P-cadherin inducer functional as a hair growth inducer.

81. (Withdrawn) The pharmaceutical composition for claim 80, wherein said P-cadherin inducer is a polynucleotide capable of directing P-cadherin expression in hair follicle cells.

82. (Withdrawn) The pharmaceutical composition for claim 80, wherein said P-cadherin inducer is an a small molecular weight organic compound.

83. (Withdrawn) The pharmaceutical composition for claim 80, wherein said P-cadherin inducer is a peptide.

84. (Withdrawn) The pharmaceutical composition for claim 80, further comprising, as an additional active ingredient, a therapeutically effective amount of an additional hair growth inducer.